

# SecureEMR version 5.0 Real World Testing Plan CY2023

---

|                 |   |
|-----------------|---|
| Developer Name: | Inmediata Health Group  |
| Product Name:   | SecureEMR   |
| Version Number: | 5.0   |
| CHPL ID:        | 15.07.07.2769.SE01.01.00.1.210408   |
| RWT Page URL:   | <a href="https://portal.inmediata.com/emr/#rwt">https://portal.inmediata.com/emr/#rwt</a> |



## Testing Plan

### Justification for Real World Testing Approach

Inmediata Health Group will be conducting a Real World Testing using SecureEMR 5.0 to measure the end-user engagement and effectiveness of the E-Prescribing [criteria 170.315(b)(3)] module of our EHR.

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

### Standards Updates (SVAP and USCDI)

NCPDP Standard V2017071

### Care Setting

Ambulatory

## Overall Expected Outcome

- Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
- Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
- Real World Testing will show a low rate of errors from our prescription hub

## Measures Used

### Measure #1

- **Certification Criteria:**

170.315(b)(3) E-Prescribing

- **Justification**

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

- **Test Methodology**

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

- **Relied upon software**

Our application relays on **Surescripts** as our e-prescription hub and **First Data Bank MedKnowledge** as our medications database to meet criteria 170.315(b)(3) E-Prescribing. We will analyze the responses from Surescripts to measure the error rate for our providers using electronic prescriptions. At this time, the real-world testing will not be considering specific medications from the FDB data source.

- **Expected Outcome**

1. Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
2. Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
3. Real World Testing will show a low rate of errors from our prescription hub

## Schedule of Key Milestones CY2023

| Key Milestone                               | Date      |
|---|-----------|
| Develop reports                             | 1/20/2024 |
| Execute preliminary reports                 | 4/14/2024 |
| Analyze preliminary reports                 | 6/16/2024 |
| Execute and analyze final reports           | 1/5/2025  |
| Create final RWT Document                   | 1/12/2025 |
| Submit final RWT Document to Drummond Group | 2/2/2025  |

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

**Authorized Representative Name:** Camilo Torres

**Authorized Representative Email:** [ctorres@inmediata.com](mailto:ctorres@inmediata.com)

**Authorized Representative Phone:** 787-783-3233

**Authorized Representative Signature:** *Camilo Torres*

**Date:** 10/20/2023